Call Now

Human JAM-A / F11R Protein (Fc Tag)

CD321,JAM,JAM1,JAMA,JCAM,KAT,PAM-1

Catalog Number P10198-H02H
Organism Species Human
Host Human Cells
Synonyms CD321,JAM,JAM1,JAMA,JCAM,KAT,PAM-1
Molecular Weight The mature recombinant human JAM-A/Fc chimera is a disulfide-linked homodimeric protein. The reduced monomer comprises 453 amino acids and has a calculated molecular mass of 50 kDa. As a result of glycosylation, the rh JAM-A/Fc monomer migrates as an approximately 61 kDa protein in SDS-PAGE under reducing conditions.
predicted N Ser 28
SDS-PAGE
Purity > 95 % as determined by SDS-PAGE
Protein Construction A DNA sequence encoding the extracellular domain (Met 1-Ala 242) of human JAM-A (NP_058642.1) precursor was expressed with the fused Fc region of human IgG1 at the C-terminus.
Bio-activity Measured by the ability of the immobilized protein to support the adhesion of Jurkat human acute T cell leukemia cells.
When 8 x 104 cells/well are added to JAM-A-Fc coated plates (2.5μg/mL, 100 μL/well)in the presence of 20 ng/mL PMA, approximately 30-40% will adhere after 30 minutes at 37℃.
Research Area Cardiovascular |Blood |Platelet
Formulation Lyophilized from sterile 100mM Glycine, 10mM NaCl, 50mM Tris, pH 7.5
1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background Junctional adhesion molecule-A (JAM-A), also known as F11 receptor (F11R) or Cluster of Differentiation 321 (CD321), is a transmembrane protein expressed at tight junctions of epithelial and endothelial cells, as well as on circulating leukocytes. JAM-A protein serves as a serotype-independent receptor for mammalian orthoreoviruses (reoviruses). It is also a ligand for the integrin LFA1, involves in leukocyte transmigration. As a cell adhesion molecule of the immunoglobulin superfamily, JAM-A protein involves in platelet adhesion, secretion and aggregation, and plays a crucial role in inflammatory thrombosis and atherosclerosis. In addition, it may be a potential therapeutic target for breast cancer.
Reference
  • Guglielmi KM, et al. (2007) Reovirus binding determinants in junctional adhesion molecule-A. J Biol Chem. 282(24): 17930-40.
  • Yeung D, et al. (2008) Decreased junctional adhesion molecule-A expression during blood-brain barrier breakdown. Acta Neuropathol. 115(6): 635-42.
  • Ong KL, et al. (2009) Elevated plasma level of soluble F11 receptor/junctional adhesion molecule-A (F11R/JAM-A) in hypertension. Am J Hypertens. 22(5): 500-5.